Drug intelligence / Profile preview

HB-110 + adefovir

Development stage: Unknown
Lead developer: Genexine
Modality: Small Molecules, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Oral, Intramuscular

Overview

**HB-110 + adefovir** is a combination therapy investigated for treating **chronic hepatitis B virus (HBV) infection**. HB-110 is a therapeutic DNA vaccine designed to enhance HBV-specific immune responses by stimulating T-cell immunity against HBV antigens. Adefovir (specifically adefovir dipivoxil) is a nucleotide analog antiviral that inhibits HBV DNA polymerase, leading to viral DNA chain termination. This combination aims to both suppress viral replication (via adefovir) and induce HBV-specific immunity (via HB-110). Clinical and animal data indicate that the combination is safe, induces T-cell responses in some patients, and may help with alanine aminotransferase normalization and HBeAg seroconversion, though immune responses in Asian patients are weaker than in Caucasian patients[3].

Brand names: Hepsera
Other names: HB-110 + adefovir dipivoxil

Targets

HBV Pol (Hepatitis B virus polymerase)Human immunodeficiency virus type 1 reverse transcriptase

Beyond the preview

Go deeper on HB-110 + adefovir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HB-110 + adefovir.

Explore the full profile